[go: up one dir, main page]

NO961322D0 - Interferoninneholdende vandig sammensetning - Google Patents

Interferoninneholdende vandig sammensetning

Info

Publication number
NO961322D0
NO961322D0 NO961322A NO961322A NO961322D0 NO 961322 D0 NO961322 D0 NO 961322D0 NO 961322 A NO961322 A NO 961322A NO 961322 A NO961322 A NO 961322A NO 961322 D0 NO961322 D0 NO 961322D0
Authority
NO
Norway
Prior art keywords
interferon
aqueous composition
containing aqueous
composition
aqueous
Prior art date
Application number
NO961322A
Other languages
English (en)
Other versions
NO961322L (no
NO316801B1 (no
Inventor
Guenter Gross
Sabino Del Terzo
Saran Kandakuri Kumar
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO961322D0 publication Critical patent/NO961322D0/no
Publication of NO961322L publication Critical patent/NO961322L/no
Publication of NO316801B1 publication Critical patent/NO316801B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Detergent Compositions (AREA)
NO19961322A 1995-04-06 1996-04-01 Interferoninneholdende vandig sammensetning NO316801B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP95105166 1995-04-06

Publications (3)

Publication Number Publication Date
NO961322D0 true NO961322D0 (no) 1996-04-01
NO961322L NO961322L (no) 1996-10-07
NO316801B1 NO316801B1 (no) 2004-05-18

Family

ID=8219166

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19961322A NO316801B1 (no) 1995-04-06 1996-04-01 Interferoninneholdende vandig sammensetning

Country Status (32)

Country Link
US (1) US5762923A (no)
EP (1) EP0736303B1 (no)
JP (1) JP2758154B2 (no)
KR (1) KR100212346B1 (no)
CN (1) CN1066065C (no)
AR (1) AR002932A1 (no)
AT (1) ATE183650T1 (no)
AU (1) AU685356B2 (no)
BR (1) BR9601276A (no)
CA (1) CA2172664C (no)
CO (1) CO4750807A1 (no)
CY (1) CY2194B1 (no)
CZ (1) CZ287626B6 (no)
DE (1) DE69603894T2 (no)
DK (1) DK0736303T3 (no)
ES (1) ES2136910T3 (no)
GR (1) GR3031775T3 (no)
HK (1) HK1012232A1 (no)
HU (1) HU227643B1 (no)
IL (1) IL117752A (no)
MA (1) MA23838A1 (no)
MY (1) MY113594A (no)
NO (1) NO316801B1 (no)
NZ (1) NZ286300A (no)
PE (1) PE38897A1 (no)
PL (1) PL183873B1 (no)
RU (1) RU2113845C1 (no)
SA (1) SA96160728B1 (no)
SG (1) SG52806A1 (no)
TR (1) TR199600287A2 (no)
TW (1) TW426523B (no)
ZA (1) ZA962553B (no)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
WO1998028007A1 (en) * 1996-12-24 1998-07-02 Biogen, Inc. Stable liquid interferon formulations
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
TWI243057B (en) * 1998-03-26 2005-11-11 Schering Corp Formulations for protection of peg-interferon alpha conjugates
US6180096B1 (en) 1998-03-26 2001-01-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
DK1069912T3 (da) * 1998-04-03 2007-11-12 Novartis Vaccines & Diagnostic Injicerbare IGF-formuleringer, der indeholder succinat som puffermiddel
BR9910505A (pt) 1998-05-15 2001-01-02 Schering Corp Terapia de combinação compreendendo ribavirina e interferon alfa em pacientes cândidos de tratamento antiviral tendo infecção crÈnica por hepatite c
BR9911076A (pt) * 1998-06-08 2001-02-20 Hoffmann La Roche Uso de peg-ifn-alfa e ribavirina para o tratamento de hepatite c crÈnica
US20030166525A1 (en) 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
IL140984A0 (en) * 1998-07-23 2002-02-10 Lilly Co Eli Fsh and fsh variant formulations, products and methods
CN1264575C (zh) 1998-08-06 2006-07-19 山景药品公司 聚乙二醇或聚环氧乙烷－尿酸氧化酶结合物及其应用
US6783965B1 (en) * 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
WO2000037096A2 (en) * 1998-12-22 2000-06-29 Schering Corporation Treatment of hepatitis c virus infections with interleukin-10
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US6362162B1 (en) 1999-04-08 2002-03-26 Schering Corporation CML Therapy
PT1535622E (pt) 1999-04-08 2009-03-19 Schering Corp Terapia de melanoma
US6923966B2 (en) * 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
US6605273B2 (en) 1999-04-08 2003-08-12 Schering Corporation Renal cell carcinoma treatment
KR100399156B1 (ko) * 1999-11-19 2003-09-26 주식회사 엘지생명과학 α-인터페론의 용액제형
CN1175901C (zh) * 1999-12-06 2004-11-17 天津华立达生物工程有限公司 一种稳定的干扰素水溶液
WO2001079442A2 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
US7208167B2 (en) * 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
EP1343518B1 (en) 2000-11-07 2009-07-22 Novartis Vaccines and Diagnostics, Inc. Stabilized interferon compositions
US8551469B2 (en) 2001-02-28 2013-10-08 Superlab Far East Limited Treatment of tumors and viral diseases with recombinant interferon alpha
CN1245215C (zh) 2001-02-28 2006-03-15 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
JP2002265383A (ja) * 2001-03-14 2002-09-18 Mitsubishi Pharma Corp インターフェロンα注射用液状製剤
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
WO2002083165A1 (fr) * 2001-04-10 2002-10-24 Sumitomo Pharmaceuticals Co., Ltd. Preparations stables destinees a etre injectees
LT4947B (lt) 2001-09-26 2002-08-26 Biotechnologijos Institutas Interferono alfa farmacinė kompozicija
PT1463751E (pt) 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina
BR0306685A (pt) 2002-05-21 2005-04-26 Daiichi Suntory Pharma Co Ltd Composição farmacêutica contendo grelina
DE602004030673D1 (de) 2003-04-02 2011-02-03 Ares Trading Sa Flüssige oder gefriergetrocknete pharmazeutische zusammensetzung enthaltend fsh und/oder lh, das nichtionische tensid poloxamer 188 und ein antibakterielles mittel
TWI272948B (en) * 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
AR044302A1 (es) * 2003-05-13 2005-09-07 Ares Trading Sa Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
WO2004112826A1 (en) 2003-06-20 2004-12-29 Ares Trading Sa Freeze-dried fsh / lh formulations
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
AR045258A1 (es) * 2003-08-21 2005-10-19 Altana Pharma Ag Un producto farmaceutico para inyeccion
US7585647B2 (en) 2003-08-28 2009-09-08 Guangwen Wei Nucleic acid encoding recombinant interferon
WO2005074546A2 (en) 2004-02-02 2005-08-18 Ambrx, Inc. Modified human growth hormone polypeptides and their uses
EP1748788A1 (en) 2004-05-17 2007-02-07 Ares Trading S.A. Hydrogel interferon formulations
UA92146C2 (ru) * 2004-06-01 2010-10-11 Эйрэс Трейдинг С.А. Стабилизированная жидкая композиция, которая содержит интерферон
US7858082B2 (en) 2004-06-01 2010-12-28 Ares Trading S.A. Method of stabilizing proteins
EP1796647B1 (en) 2004-08-12 2010-08-11 Schering Corporation Stable pegylated interferon formulation
WO2006022301A1 (ja) * 2004-08-24 2006-03-02 Daiichi Asubio Pharma Co., Ltd. 生理活性ペプチド液状製剤
PL215285B1 (pl) 2005-04-11 2013-11-29 Savient Pharmaceuticals Inc Wyizolowana, skrócona ssacza urykaza, obejmujacy ja koniugat glikol polietylenowy-urykaza, sposób jej wytwarzania, zawierajaca ja kompozycja farmaceutyczna i jej zastosowanie oraz kodujacy urykaze wyizolowany kwas nukleinowy, jego wektor i obejmujaca go komórka gospodarza
ES2302402B1 (es) 2005-06-16 2009-05-08 Proyecto De Biomedicina Cima, S.L. Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa.
AU2006295340B2 (en) 2005-08-05 2010-11-11 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
CU23432B6 (es) 2005-11-02 2009-10-16 Ct Ingenieria Genetica Biotech Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
WO2008026044A2 (en) * 2006-08-31 2008-03-06 Wockhardt Research Centre Pharmaceutical compositions of bupropion
RU2475265C2 (ru) 2007-01-16 2013-02-20 Эбботт Лэборетриз Способы лечения псориаза
WO2008145323A1 (en) * 2007-05-31 2008-12-04 F. Hoffmann-La Roche Ag Pharmaceutical formulation for interferons
WO2009030065A1 (zh) * 2007-09-04 2009-03-12 Biosteed Gene Expression Tech. Co., Ltd. 聚乙二醇修饰的干扰素α2a及其制备方法和应用
ES2382124T3 (es) * 2007-09-04 2012-06-05 Biosteed Gene Expression Tech. Co., Ltd. Interferón alfa 2b modificado con polietilenglicol y método de preparación y aplicaciones de este
EP2212432A4 (en) * 2007-10-22 2011-10-19 Schering Corp COMPLETELY HUMAN ANTI-VEGF ANTIBODIES AND USE PROCEDURES
PT2234645E (pt) 2007-12-20 2012-05-21 Merck Serono Sa Formulações de peg-interferão-beta
EP2305309A2 (en) 2008-06-13 2011-04-06 Proyecto de Biomedicina Cima, S.L. Conjugates for the administration of biologically active compounds
JP2012502906A (ja) * 2008-09-17 2012-02-02 ネクター セラピューティックス オリゴマー−プロテアーゼ阻害剤コンジュゲート
BRPI1010069A2 (pt) 2009-06-25 2016-03-15 Savient Pharmaceuticals Inc "método para prevenir reações à infusão durante terapia por uricase peguilada em pacientes; e método para diagnosticar se um paciente tratado com uricase peguilada desenvolverá reações à infusão ou desenvolverá liberação de uricase peguilada mediada por anticorpo sem a medição de títulos de anticorpos anti-peg e anti-uricase peguilada"
CN102101886A (zh) 2009-12-18 2011-06-22 四川辉阳生命工程股份有限公司 构象改变的重组干扰素晶体、其三维结构及应用
RU2447083C1 (ru) * 2010-07-20 2012-04-10 Закрытое Акционерное Общество "Биокад" НОВЫЙ ФУНКЦИОНАЛЬНО АКТИВНЫЙ ВЫСОКООЧИЩЕННЫЙ СТАБИЛЬНЫЙ КОНЪЮГАТ ИНТЕРФЕРОНА α С ПОЛИЭТИЛЕНГЛИКОЛЕМ, ПРЕДСТАВЛЕННЫЙ ОДНИМ ПОЗИЦИОННЫМ ИЗОМЕРОМ ПЭГ-NαH-ИФН, С УМЕНЬШЕННОЙ ИММУНОГЕННОСТЬЮ, С ПРОЛОНГИРОВАННЫМ БИОЛОГИЧЕСКИМ ДЕЙСТВИЕМ, ПРИГОДНЫЙ ДЛЯ МЕДИЦИНСКОГО ПРИМЕНЕНИЯ, И ИММУНОБИОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ
KR101303388B1 (ko) * 2010-10-26 2013-09-03 한미사이언스 주식회사 지속형 인터페론 알파 결합체의 액상 제제
CN102526758B (zh) * 2012-02-23 2013-02-13 北京三元基因工程有限公司 一种聚乙二醇化干扰素稳定的水溶液
TW201427681A (zh) 2013-01-07 2014-07-16 Superlab Far East Ltd 用空間構象改變的重組干擾素治療腫瘤的方法
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
JP6445169B2 (ja) * 2014-09-23 2018-12-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ α型インターフェロンを含有する安定したベンジルアルコールフリーの水溶液製剤
US12121566B2 (en) 2019-01-30 2024-10-22 Horizon Therapeutics Usa, Inc. Methods for treating gout
RU2768656C1 (ru) * 2021-09-10 2022-03-24 Илья Александрович Марков Противовирусное средство в жидкой форме и способ его приготовления

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61277633A (ja) * 1985-05-31 1986-12-08 Toray Ind Inc インタ−フエロン組成物
EP0284249A1 (en) * 1987-03-13 1988-09-28 Interferon Sciences, Inc. Lyophilized lymphokine composition
IL88233A (en) * 1987-11-03 1993-08-18 Genentech Inc Gamma interferon formulation
EP0396777A4 (en) * 1988-11-14 1991-03-13 Otsuka Pharmaceutical Co., Ltd. Interferon preparation for nasal administration
JPH0651642B2 (ja) * 1988-11-14 1994-07-06 大塚製薬株式会社 インターフェロン経鼻投与用製剤
CA2033714A1 (en) * 1990-01-25 1991-07-26 Alberto Ferro Pharmaceutical preparations
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
IL109350A (en) * 1993-05-12 2001-01-28 Genentech Inc Stable liquid preparations of gamma interferon

Also Published As

Publication number Publication date
IL117752A (en) 2000-11-21
IL117752A0 (en) 1996-08-04
BR9601276A (pt) 1998-01-13
CZ287626B6 (en) 2001-01-17
SA96160728B1 (ar) 2005-05-04
NO961322L (no) 1996-10-07
AU5044696A (en) 1996-10-17
CY2194B1 (en) 2002-11-08
NZ286300A (en) 1997-05-26
HU9600857D0 (en) 1996-05-28
AR002932A1 (es) 1998-05-27
MA23838A1 (fr) 1996-12-31
JP2758154B2 (ja) 1998-05-28
HUP9600857A2 (en) 1997-08-28
CZ99496A3 (en) 1996-10-16
EP0736303A3 (en) 1997-02-26
ZA962553B (en) 1996-10-07
AU685356B2 (en) 1998-01-15
EP0736303A2 (en) 1996-10-09
NO316801B1 (no) 2004-05-18
CN1141808A (zh) 1997-02-05
PE38897A1 (es) 1997-10-04
EP0736303B1 (en) 1999-08-25
KR100212346B1 (ko) 1999-08-02
ATE183650T1 (de) 1999-09-15
JPH08283176A (ja) 1996-10-29
DK0736303T3 (da) 2000-01-10
CA2172664C (en) 2000-10-03
DE69603894T2 (de) 2000-04-20
RU2113845C1 (ru) 1998-06-27
US5762923A (en) 1998-06-09
HK1012232A1 (en) 1999-07-30
CN1066065C (zh) 2001-05-23
TR199600287A2 (tr) 1997-03-21
ES2136910T3 (es) 1999-12-01
CA2172664A1 (en) 1996-10-07
HUP9600857A3 (en) 1998-01-28
CO4750807A1 (es) 1999-03-31
TW426523B (en) 2001-03-21
MY113594A (en) 2002-04-30
KR960037063A (ko) 1996-11-19
DE69603894D1 (de) 1999-09-30
HU227643B1 (en) 2011-10-28
SG52806A1 (en) 1998-09-28
GR3031775T3 (en) 2000-02-29
PL313655A1 (en) 1996-10-14
PL183873B1 (pl) 2002-07-31

Similar Documents

Publication Publication Date Title
NO961322L (no) Interferoninneholdende vandig sammensetning
BR9404552A (pt) Composição aquosa
DE69512553D1 (de) Wässrige Beschichtungszusammensetzung
FI974241A0 (fi) BPM-15 -koostumukset
DE69705979D1 (de) Wässrige Besichtungszusammentsetzung
BR9406411A (pt) Composição de xampu
DE69406591D1 (de) Wässrige Überzugszusammensetzung
DE69632283D1 (de) Wässrige Lackzusammensetzung
BR9609320A (pt) Cianofeniluracilas substituidas
BR9508318A (pt) Composição impadora concentrada
BR9607058A (pt) Composição
BR9606809A (pt) Composição inseticidamente ativa
DE69603707D1 (de) Wässrige anstrichzusammensetzung
NO981568D0 (no) Randtennings-tennsatssammensetninger
DK0748583T3 (da) Mejetærsker
BR9612172A (pt) Composição aquosa de revestimento
DE69617029D1 (de) Organoton-zusammensetzungen
BR9608486A (pt) Composição de revestimento aquosa
PT728814E (pt) Composicao betuminosa
BR9609903A (pt) ComposiçÃo inseticidamente ativa
BR9609671A (pt) Amino uracilas substituídas
DE69616374D1 (de) Germizide zusammensetzung
BR9702241A (pt) Composição aquosa
DE69410011D1 (de) Wässrige Beschichtungsmittelzusammensetzung
DE69500604D1 (de) Wässrige Primerzusammensetzung

Legal Events

Date Code Title Description
MK1K Patent expired